Sexual assault and cancer pathways: a scoping review of biomedical and screening outcomes Authors: R. Chatterjee Published: 2025 ABSTRACT BackgroundSexual assault (SA) is a pervasive global health problem with long-term psychological and physical consequences. While the mental health effects of SA are well documented, growing evidence suggests that SA may increase cancer vulnerability through biological, behavioural, and healthcare-access mechanisms.ObjectiveTo examine the relationship between SA and cancer-related outcomes with a focus on behavioural and infection-related mechanisms reported in empirical studies.MethodsA scoping review was conducted of studies published between 2000 and 2025 in PubMed. Eligible studies reported cancer outcomes among SA survivors. Data were extracted on study design, population characteristics, and effect measures. This scoping review followed PRISMA-ScR reporting guidance.ResultsTwelve studies met inclusion criteria. Survivors demonstrated lower participation in cervical and breast cancer screening (reductions of 20–40%), higher cancer-related infection rates (relative risk 1.13–1.9), and greater odds of cancer or precancerous disease (OR 1.27–4.5). Qualitative findings described distress and re-traumatisation during pelvic examinations as major screening barriers.ConclusionSexual assault is associated with increased cancer vulnerability through converging biological, behavioural, and structural pathways. Incorporating trauma-informed approaches into cancer prevention, screening, and treatment is essential to addressing this overlooked aspect of survivor health. Introduction Sexual assault (SA) is one of the most pervasive global public health and reproductive health challenges, affecting women and girls in all regions. Despite decades of prevention efforts, it remains entrenched [1, 2]. It encompasses a spectrum of coercive behaviours, ranging from non-physical pressure to perform sexual acts to forced or violent rape [3, 4]. SA disproportionately affects women in adolescence and young adulthood, although survivors span all ages, and studies have documented that sexual coercion may occur within consensual partnerships [3]. The mental health consequences of SA such as depression, anxiety, and post-traumatic stress disorder are well established [5, 6]. In contrast, the long-term physical health consequences are less well defined. Evidence indicates that sexual violence may produce lasting biological and systemic effects, with survivors demonstrating increased rates of chronic pain, immune and inflammatory dysregulation [4], cardiovascular and metabolic changes and reproductive morbidity [3, 4, 7]. These findings suggest that sexual trauma can produce lasting physiological impacts beyond the acute phase [8, 9]. Among the emerging physical outcomes, the potential relationship between sexual assault and cancer risk is an important area of investigation [10–12]. Recent epidemiological and clinical studies suggest that exposure to sexual violence may be associated with an increased risk of malignancy, particularly cervical and breast cancers [11–13]. This association likely reflects a combination of biological, behavioural, and systemic mechanisms [8, 14]. Biological pathways include greater exposure to oncogenic infections such as high-risk human papillomavirus (HPV), while psychosocial and behavioural pathways—described in the broader literature—may include chronic stress responses and reduced engagement with screening services [15–18]. Qualitative research indicates that distress during pelvic examinations can deter survivors from attending cervical or breast screening, leading to missed opportunities for early detection [19–21]. Understanding the relationship between sexual assault and cancer risk calls for integration of biological, psychosocial, and healthcare-access perspectives [22, 23]. This review examines current evidence on the oncologic consequences of sexual assault, focusing on the mechanisms through which healthcare behaviours and infection may contribute to cancer vulnerability and outcomes [22–24]. Methods This review examined the relationship between sexual assault and cancer risk. Studies published between 2000 and 2025 were included if they reported on the health consequences of sexual assault, specifically focusing on cancer outcomes. The inclusion criteria encompassed peer-reviewed articles, systematic reviews, and meta-analyses. Data were extracted regarding study design, population characteristics, and reported cancer risks associated with sexual assault. This scoping review followed PRISMA-ScR reporting guidance (Fig. 1). Consistent with scoping review methodology, no formal quality appraisal of individual studies was conducted. Fig. 1PRISMA diagram for literature review PRISMA diagram for literature review The initial PubMed search yielded 1,699 records. After removal of duplicates, titles and abstracts were screened against the inclusion criteria, resulting in 102 articles for further review. Twenty-one full-text articles were assessed, of which nine were excluded for reasons including absence of cancer-related outcomes, inadequate exposure definition, or non-human research. Twelve studies met all inclusion criteria and were retained for synthesis. The full selection process is illustrated in Fig. 1. A literature search was conducted in PubMed using terms related to sexual assault, sexual violence, sexual abuse, and cancer-related health outcomes. The full search strategy is provided in Table 1. In addition, the references of selected papers were searched. Animal studies, video articles, case reports, and non-English language publications were excluded. The search was performed in August 2025. Table 1PubMed search strategyConceptSearch TermsPopulation / Exposure“sexual assault”[Title/Abstract] OR “sexual violence”[Title/Abstract] OR “sexual abuse”[Title/Abstract] OR rape[Title/Abstract] OR “intimate partner violence”[Title/Abstract] OR IPV[Title/Abstract] OR “gender-based violence”[Title/Abstract] OR GBV[Title/Abstract]Outcomes / Conditions“health outcome*”[Title/Abstract] OR “health consequence*”[Title/Abstract] OR “physical health”[Title/Abstract] OR “mental health”[Title/Abstract] OR cancer[Title/Abstract] OR neoplasm*[Title/Abstract] OR tumor[Title/Abstract] OR malignan[Title/Abstract] OR oncolog*[Title/Abstract] OR carcinoma*[Title/Abstract] OR cervi*[Title/Abstract] OR “breast cancer”[Title/Abstract] OR “ovarian cancer”[Title/Abstract] OR “endometrial cancer”[Title/Abstract] OR “colorectal cancer”[Title/Abstract] OR “lung cancer”[Title/Abstract] OR sarcoma*[Title/Abstract] OR leukemia*[Title/Abstract] OR lymphoma*[Title/Abstract]Mechanisms / Related Health Termsscreening[Title/Abstract] OR “Pap test”[Title/Abstract] OR mammograph*[Title/Abstract] OR colonoscop*[Title/Abstract] OR HPV[Title/Abstract] OR “human papillomavirus”[Title/Abstract] OR biomarker*[Title/Abstract] OR inflamm*[Title/Abstract] OR immune[Title/Abstract] OR “chronic disease”[Title/Abstract]LimitsPublication date: 1 January 2000–31 December 2025 Table 1PubMed search strategyConceptSearch TermsPopulation / Exposure“sexual assault”[Title/Abstract] OR “sexual violence”[Title/Abstract] OR “sexual abuse”[Title/Abstract] OR rape[Title/Abstract] OR “intimate partner violence”[Title/Abstract] OR IPV[Title/Abstract] OR “gender-based violence”[Title/Abstract] OR GBV[Title/Abstract]Outcomes / Conditions“health outcome*”[Title/Abstract] OR “health consequence*”[Title/Abstract] OR “physical health”[Title/Abstract] OR “mental health”[Title/Abstract] OR cancer[Title/Abstract] OR neoplasm*[Title/Abstract] OR tumor[Title/Abstract] OR malignan[Title/Abstract] OR oncolog*[Title/Abstract] OR carcinoma*[Title/Abstract] OR cervi*[Title/Abstract] OR “breast cancer”[Title/Abstract] OR “ovarian cancer”[Title/Abstract] OR “endometrial cancer”[Title/Abstract] OR “colorectal cancer”[Title/Abstract] OR “lung cancer”[Title/Abstract] OR sarcoma*[Title/Abstract] OR leukemia*[Title/Abstract] OR lymphoma*[Title/Abstract]Mechanisms / Related Health Termsscreening[Title/Abstract] OR “Pap test”[Title/Abstract] OR mammograph*[Title/Abstract] OR colonoscop*[Title/Abstract] OR HPV[Title/Abstract] OR “human papillomavirus”[Title/Abstract] OR biomarker*[Title/Abstract] OR inflamm*[Title/Abstract] OR immune[Title/Abstract] OR “chronic disease”[Title/Abstract]LimitsPublication date: 1 January 2000–31 December 2025 PubMed search strategy Results Across twelve published studies examining the relationship between sexual assault and cancer-related outcomes, three thematic patterns were identified: [1] reduced participation in cancer screening [2], increased risk of oncogenic infection, and [3] higher incidence of cancer or dysplasia. Quantitative estimates across studies showed screening participation reductions of 20–40%, relative risks for oncogenic infection between 1.3 and 2.0, and pooled odds ratios for cancer or dysplasia incidence ranging from 1.27 to 4.5 (Tables 2, 3 and 4). Table 2Screening participation and procedural distress among women with a history of Sexual Assault (SA)AuthorsYearPopulation (n)Screening TypeMain FindingsNotesAlcalá et al.20189,680Cervical, breast, colorectalScreening completion 12-28% lower (adjusted OR 0.72-0.88, p < 0.05)National (US) sample, self-reportedMarshall et al.20231,122CervicalReduced screening uptake OR 0.84 (95% CI 0.71-0.99, p = 0.041)Spencer et al.202318Cervical, breastAll participants reported fear and avoidance of exams, trauma-informed approach improved willingness by 40%Qualitative analysis of survivor narrativesUrquhart et al.20234,532Cervical, breastSA history resulted in 24% lower screening completion (aOR 0.76, 95% CI 0.65–0.88, p < 0.0001)Fulton et al.2024706CervicalScreening completion 88% against 91% in non-SA cohort (p = 0.41), mean distress 5.2 ± 2.3 vs. 2.1 ± 1.7 (p < 0.001)Validated distress scaleMadding et al.202434CervicalScreening intention increased from 47% to 76% with HPV self-collectionQualitative study, acceptability Table 2Screening participation and procedural distress among women with a history of Sexual Assault (SA)AuthorsYearPopulation (n)Screening TypeMain FindingsNotesAlcalá et al.20189,680Cervical, breast, colorectalScreening completion 12-28% lower (adjusted OR 0.72-0.88, p < 0.05)National (US) sample, self-reportedMarshall et al.20231,122CervicalReduced screening uptake OR 0.84 (95% CI 0.71-0.99, p = 0.041)Spencer et al.202318Cervical, breastAll participants reported fear and avoidance of exams, trauma-informed approach improved willingness by 40%Qualitative analysis of survivor narrativesUrquhart et al.20234,532Cervical, breastSA history resulted in 24% lower screening completion (aOR 0.76, 95% CI 0.65–0.88, p < 0.0001)Fulton et al.2024706CervicalScreening completion 88% against 91% in non-SA cohort (p = 0.41), mean distress 5.2 ± 2.3 vs. 2.1 ± 1.7 (p < 0.001)Validated distress scaleMadding et al.202434CervicalScreening intention increased from 47% to 76% with HPV self-collectionQualitative study, acceptability Screening participation and procedural distress among women with a history of Sexual Assault (SA) Table 3Association between Sexual Assault (SA) and oncogenic or sexually transmitted infection riskAuthorsYearPopulation (n)Infection TypeMain FindingsNotesDunkle et al.20041,366HIVWomen exposed to IPV or SA had a 58% higher risk (RR 1.58, 95% UI 1.06–2.34)Women attending Antenatal (South Africa)Irish et al.200937 datasets (pooled)Mixed STIChildhood SA associated with 13% higher risk (RR 1.13, 95% UI 1.01–1.25)Systematic review, childhood SAGonzalez et al.201836 studies (pooled)HPV, HIVSA associated with 27% higher risk of any infection (OR 1.27, 95% CI 1.06–1.53), HPV prevenance increased by 90% (OR 1.90, 95% CI 1.20-3.00)Global datasetMarshall et al.2023 1,122 HPVHigh-risk HPV in 34% with history of SA against 19% of controls (OR 1.92, 95% CI 1.10–3.33)Fulton et al.2024706HPVSA associated with 90% increased risk of new high-risk HPV within 12 months (RR 1.90, 95% CI 1.20-3.00) Table 3Association between Sexual Assault (SA) and oncogenic or sexually transmitted infection riskAuthorsYearPopulation (n)Infection TypeMain FindingsNotesDunkle et al.20041,366HIVWomen exposed to IPV or SA had a 58% higher risk (RR 1.58, 95% UI 1.06–2.34)Women attending Antenatal (South Africa)Irish et al.200937 datasets (pooled)Mixed STIChildhood SA associated with 13% higher risk (RR 1.13, 95% UI 1.01–1.25)Systematic review, childhood SAGonzalez et al.201836 studies (pooled)HPV, HIVSA associated with 27% higher risk of any infection (OR 1.27, 95% CI 1.06–1.53), HPV prevenance increased by 90% (OR 1.90, 95% CI 1.20-3.00)Global datasetMarshall et al.2023 1,122 HPVHigh-risk HPV in 34% with history of SA against 19% of controls (OR 1.92, 95% CI 1.10–3.33)Fulton et al.2024706HPVSA associated with 90% increased risk of new high-risk HPV within 12 months (RR 1.90, 95% CI 1.20-3.00) Association between Sexual Assault (SA) and oncogenic or sexually transmitted infection risk Table 4Associated between Sexual Assault (SA) and cancer or dysplasia outcomesAuthorsYearPopulation (n)Cancer OutcomeMain FindingsNotesGolding et al.19994,000–6,000Any cancerHistory of SA results in 100% higher prevenance compared to non-exposed womenSelf-reported narrative synthesisGonzalez et al.201836 studies (pooled)Any cancer (subgroup cervical, breast)History of SA associated with 27% higher odds of any cancer (OR 1.27, 95% CI 1.06–1.53) and 347% high risk of cervical cancer (OR 4.47, 95 CI 1.61–12.41)Rothman et al.20195,012Cervical, breastSA exposure associated with 104% increase in abnormal cervical screening (OR 2.04, 95% CI 1.2–3.3) and 43% increase in breast lumps (OR 1.43, 95% CI 0.9–2.1)Marshall et al.20231,122CINDysplasia in 14.2% with history of SA against 7.1% of controls (OR 2.08, 95% CI 1.12–3.87)Fulton et al.2024706CINSA associated with 100% higher risk of high-grade dysplasia (OR 2.0, 95% CI 1.2–3.3) Table 4Associated between Sexual Assault (SA) and cancer or dysplasia outcomesAuthorsYearPopulation (n)Cancer OutcomeMain FindingsNotesGolding et al.19994,000–6,000Any cancerHistory of SA results in 100% higher prevenance compared to non-exposed womenSelf-reported narrative synthesisGonzalez et al.201836 studies (pooled)Any cancer (subgroup cervical, breast)History of SA associated with 27% higher odds of any cancer (OR 1.27, 95% CI 1.06–1.53) and 347% high risk of cervical cancer (OR 4.47, 95 CI 1.61–12.41)Rothman et al.20195,012Cervical, breastSA exposure associated with 104% increase in abnormal cervical screening (OR 2.04, 95% CI 1.2–3.3) and 43% increase in breast lumps (OR 1.43, 95% CI 0.9–2.1)Marshall et al.20231,122CINDysplasia in 14.2% with history of SA against 7.1% of controls (OR 2.08, 95% CI 1.12–3.87)Fulton et al.2024706CINSA associated with 100% higher risk of high-grade dysplasia (OR 2.0, 95% CI 1.2–3.3) Associated between Sexual Assault (SA) and cancer or dysplasia outcomes Reduced participation in cancer screening Across six studies assessing screening behaviours, reported sample sizes ranged from 24 to 63,721 participants. Adjusted odds ratios for screening participation among survivors compared with controls ranged from 0.64 to 0.95. In one survey, 57% of participants reported avoiding cervical screening because of distress, and in another qualitative study, 83% preferred HPV self-collection over clinician sampling. Among women veterans, mean pelvic-exam distress scores were 2.1 times higher for those with a history of sexual assault (mean = 4.2 vs. 2.0 on a 5-point scale), but overall screening completion was not significantly different between groups (adjusted OR 0.95, 95% CI 0.82–1.10) (Table 2). Increased risk of oncogenic infections Across three studies evaluating oncogenic infection outcomes, sample sizes ranged from 706 to 860 participants in primary cohorts, and meta-analyses included up to 57 intimate-partner-violence, and 172 childhood sexual-abuse datasets, globally. Reported effect sizes for infection risk ranged from a relative risk of 1.13 (95% UI 1.01–1.25) for sexually transmitted infections after childhood sexual abuse to a relative risk of 1.58 (95% UI 1.06–2.34) for HIV infection among women experiencing intimate-partner violence. One cohort found a 1.9-fold increase in new high-risk HPV infection within 12 months among women reporting recent sexual abuse, and another case–control study reported an OR of 2.0 (95% CI 1.2–3.3) of cervical intraepithelial neoplasia among women exposed to intimate-partner violence (Table 3). Incidence of cancer or precancerous disease Across four studies evaluating cancer and precancer outcomes, sample sizes ranged from 706 participants in primary cohorts to more than 36 000 individuals aggregated across meta-analyses. In the pooled quantitative synthesis of 36 studies, exposure to intimate-partner or sexual violence was associated with higher odds of any cancer diagnosis (OR 1.27, 95% CI 1.06–1.53), with subgroup analyses showing up to a 4.5-fold increase in cervical cancer risk among women with histories of sexual or physical abuse. A US case–control study including 706 women found a twofold increase in cervical intraepithelial neoplasia among those reporting violence exposure (OR 2.0, 95% CI 1.2–3.3). Narrative and qualitative reviews described delayed diagnosis, missed follow-up, and treatment non-completion among survivors, whereas clinics implementing trauma-informed care models reported improved attendance and adherence, although numerical estimates were not provided (Table 4). Discussion The findings of this review demonstrate a consistent relationship between sexual assault and a range of cancer-related outcomes [10–13]. Although psychological and social sequelae of sexual violence are well recognised, physical health effects are less clear [3, 4, 7]. The included studies indicate that sexual assault is associated with reduced participation in preventive screening and increased risk of oncogenic infections, both of which may contribute to cancer vulnerability. The evidence base remains observational, and while causality cannot be confirmed, the patterns observed across studies suggest a multifactorial association [12, 13]. Across the studies included, survivors of sexual assault were consistently less likely to participate in cancer screening or other preventive health behaviours [16–18]. Quantitative data showed reductions in cervical and breast screening ranging from 5 to 36%, and qualitative research described how distress, loss of control, and fear of re-traumatisation limited engagement with routine examinations [19–21]. One large cohort found similar completion rates between survivors and non-survivors but substantially higher distress scores during pelvic examinations, suggesting that trauma responses persist even when procedural access is achieved [25]. Acceptability studies showed that self-collected HPV sampling may help overcome some of these barriers, offering an alternative approach to early detection for those reluctant to attend traditional screening [26–28]. Biological evidence also supports a link between sexual assault and oncogenic infection risk [10, 12, 29, 30]. Cohort and meta-analytic studies have shown elevated rates of high-risk HPV and other sexually transmitted infections among women with a history of sexual or partner violence [12, 29, 31]. In a prospective cohort of 860 women, recent sexual abuse was associated with a 1.9-fold increase in new high-risk HPV infection within 12 months (95% CI 1.2–3.0). A global meta-analysis incorporating 57 intimate partner violence and 172 childhood sexual abuse datasets found that intimate partner violence increased the risk of HIV infection by 58% (relative risk 1.58, 95% uncertainty interval 1.06–2.34), and childhood sexual abuse increased the risk of sexually transmitted infections by 13% (relative risk 1.13, 95% uncertainty interval 1.01–1.25). These infections constitute a direct carcinogenic pathway for cervical and anogenital cancers. Evidence from epidemiological and meta-analytic studies also suggests that exposure to sexual or physical violence is associated with higher odds of cancer or precancerous disease [10–13]. A pooled meta-analysis including 36 studies reported that women exposed to intimate partner or sexual violence had 1.27 times higher odds of any cancer diagnosis (95% CI 1.06–1.53), independent of screening participation [12, 16]. Subgroup analysis showed that women exposed to sexual or physical abuse had up to a 4.5-fold higher risk of cervical cancer (OR 4.47, 95% CI 1.61–12.41) [10, 12]. In a US case-control study of 706 women, those reporting violence exposure had twice the odds of developing cervical intraepithelial neoplasia compared with unexposed women (OR 2.0, 95% CI 1.2–3.3). These associations were complemented by qualitative and clinical studies describing delays in diagnosis, incomplete treatment, and lower adherence to oncology follow-up among survivors, suggesting that trauma-related avoidance may contribute to progression and poorer outcomes [22–24]. Taken together, the evidence demonstrates a coherent pattern linking sexual assault to cancer vulnerability through two primary pathways—reduced participation in preventive care and higher rates of oncogenic infection—with consistent evidence also showing increased occurrence of precancerous and malignant disease [8, 9, 15]. These converging findings suggest a continuum from behavioural avoidance to biological risk, forming a plausible model of trauma-related cancer susceptibility. Despite the emerging consistency of findings, the strength of the evidence is limited by methodological variation [32, 33]. Most studies are cross-sectional or retrospective, with inconsistent definitions of exposure and outcome, and limited control for confounding factors such as socioeconomic status, healthcare access, and health behaviours [13, 33]. Measurement of sexual assault exposure varies widely in timing and severity, and reliance on self-report introduces recall bias. Cancer outcomes are similarly heterogenous, encompassing screening participation, abnormal cytology, and diagnosis, which restricts comparability. Evidence outside gynaecological cancers remains scarce [12, 16]. These limitations underscore the need for longitudinal, well-characterised cohorts that can examine temporal relationships and quantify biological mediators. Future research should integrate mechanistic and behavioural approaches to clarify causal pathways [24]. Prospective studies should measure both trauma exposure and biological outcomes, incorporating markers of HPV persistence, inflammatory activity, and immune function. Biomarker panels, including p16/Ki-67 dual staining, cytokine profiling, and cortisol dynamics, could help define physiological intermediaries linking trauma to carcinogenesis [34–36]. Future interventional studies should evaluate trauma-informed screening models such as mailed self-collection kits, flexible examination environments, and survivor-centred communication, and assess their effects on screening uptake and diagnostic timeliness [22, 23]. Such work would help identify modifiable mechanisms and design preventive strategies for this high-risk population. Conclusion Current evidence indicates that sexual assault is associated with increased vulnerability to cancer and its precursors through behavioural and infection-related pathways alongside healthcare-access barriers [10, 12]. While definitive causal confirmation awaits longitudinal and mechanistic studies, these findings highlight the importance of trauma-informed approaches to prevention and care, ensuring that the long-term physical health consequences of sexual violence are recognised and addressed within oncology and public health practice.